Itaan Pharma Profile
Key Indicators
- Authorised Capital ₹ 50.00 Cr
as on 27-10-2024
- Paid Up Capital ₹ 33.79 Cr
as on 27-10-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 46.54 Cr
as on 27-10-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 319.18%
(FY 2023)
About Itaan Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 33.79 Cr.
The company currently has active open charges totaling ₹46.54 Cr.
The Key Managerial Personnel (KMP) at Itaan Pharma Private Limited India is Saad Khan as COMPANY SECRETARY. Chandu Kankanala, Chirukuri Ramana, and Prasanna Sagar serve as directors at the Company.
- CIN/LLPIN
U24230AP2020PTC114523
- Company No.
114523
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Guntur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Itaan Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chirukuri Ramana  | Managing Director | 04-May-2020 | Current |
| Saad Khan | Company Secretary | 26-Feb-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chandu Kankanala | Director | 04-May-2020 | Current |
| Prasanna Sagar | Director | 20-Apr-2022 | Current |
Financial Performance of Itaan Pharma.
Itaan Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Itaan Pharma?
In 2023, Itaan Pharma had a promoter holding of 52.50% and a public holding of 47.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Aug 2023 | ₹1.54 Cr | Open |
Others Creation Date: 15 Mar 2023 | ₹45.00 Cr | Open |
How Many Employees Work at Itaan Pharma?
Itaan Pharma has a workforce of 80 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Itaan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Itaan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
